ConductScience.org, home

Trial · NCT00855413

Results by group38

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Number of Participants With Virologic ResponseAcute HIV Infection Treatment Group13Participants
Number of Participants With Virologic ResponseAcute HIV Infection Treatment Group9Participants
Median Change in CD4 Cell Count From Week 0 to Week 24.Acute HIV Infection Treatment Group158Full Range -281 to 916cells/mm^3
Median Change in CD4 Cell Count From Week 0 to Week 48.Acute HIV Infection Treatment Group349Full Range 7 to 495cells/mm^3
HIV RNA Levels Immediately Prior to Initiating Study Treatment.Acute HIV Infection Treatment Group1,000,000Full Range 22,858 to 29,807,640copies/mL
Median Time to HIV RNA Suppression to <200 Copies/mLAcute HIV Infection Treatment Group59Full Range 15 to 187days
HIV RNA Detection in SemenAcute HIV Infection Treatment Group2541Full Range 0 to 7470copies/mL
Number of Participants Who Stopped Study Treatment Due to Adverse Event or IntoleranceAcute HIV Infection Treatment Group1Participants
Adverse Events Possibly or Definitely Related to Study Treatment Through Week 48Acute HIV Infection Treatment Group13adverse events
Maximum Etravirine Exposure in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar PunctureAcute HIV Infection Treatment Group25ng/mL
Minimum Etravirine Exposure in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar PunctureAcute HIV Infection Treatment Group4ng/mL
Maximum Darunavir Exposure in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar PunctureAcute HIV Infection Treatment Group240ng/mL
Minimum Darunavir Exposure in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar PunctureAcute HIV Infection Treatment Group10ng/mL
Maximum Ritonavir Exposure in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar PunctureAcute HIV Infection Treatment Group22ng/mL
Minimum Ritonavir Exposure Range in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar PunctureAcute HIV Infection Treatment Group2ng/mL
Maximum Etravirine Exposure in Semen Among Participants Who Consented to an Optional Collection of SemenAcute HIV Infection Treatment Group185ng/mL
Minimum Etravirine Exposure in Semen Among Participants Who Consented to an Optional Collection of SemenAcute HIV Infection Treatment Group12ng/mL
Maximum Darunavir Exposure in Semen Among Participants Who Consented to an Optional Collection of SemenAcute HIV Infection Treatment Group1296ng/mL
Minimum Darunavir Exposure Range in Semen Among Participants Who Consented to an Optional Collection of SemenAcute HIV Infection Treatment Group9ng/mL
Maximum Ritonavir Exposure in Semen Among Participants Who Consented to an Optional Collection of SemenAcute HIV Infection Treatment Group22ng/mL

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00855413/results